A small phase 2 trial found that oxaloacetate — a nutritional supplement — significantly improved cognitive function in breast cancer survivors struggling with post-treatment brain fog. All 16 evaluable participants moved from an impaired to a normal cognitive range after just 8 weeks. Fatigue and physical functioning also improved meaningfully.
For breast cancer survivors dealing with lingering cognitive difficulties after treatment — often called "chemo brain" — a nutritional supplement called oxaloacetate may offer real relief. A phase 2 trial published in JCO Oncology Advances found that 500 mg of oxaloacetate taken twice daily for 8 weeks led to clinically significant improvements in perceived cognitive function in all 16 evaluable participants, moving them from an impaired range to a normative one.
Beyond cognition, participants also reported major reductions in fatigue and improvements in physical functioning. Neuropsychological testing backed up the self-reported gains, showing measurable improvements in executive function and processing speed.
By the Numbers:
Why it matters: Cancer-related cognitive impairment affects a large proportion of breast cancer survivors and has few proven treatment options. While this trial was small and lacked a placebo control, the results are promising enough to warrant a larger, randomized trial — and could eventually offer survivors a safe, accessible tool to reclaim mental clarity.
